Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Variant||KMT2A - AFDN|
|Protein Effect||gain of function|
|Gene Variant Descriptions||KMT2A-AFDN (also referred to as MLL-AF6) results from the fusion of KMT2A and AFDN, which leads to nuclear localization of Raf6, activation of Ras signaling in culture (PMID: 24695851), and leukemogenesis in mouse models (PMID: 29062045). KMT2A-AFDN has been identified in acute myelomonocytic leukemia (PMID: 30132801) and pediatric acute myeloid leukemia (PMID: 29105243).|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KMT2A - AFDN||acute myeloid leukemia||predicted - sensitive||CYC065||Preclinical - Cell culture||Actionable||In a preclinical study, an acute myeloid leukemia cell line harboring KMT2A-AFDN was sensitive to treatment with CYC065 (Fadraciclib) in culture, demonstrating decreased cell viability (PMID: 32645016).||32645016|
|Molecular Profile||Protein Effect||Treatment Approaches|
|KMT2A - AFDN||gain of function|